Aggregated price index with volume information
Summary:
- Pharmaceuticals: Other stocks down 1.1% on average while median return down 0.9% in a day
- Pharmaceuticals: Other stocks down 6.1% on average while median return down 4.2% in a week
- Pharmaceuticals: Other stocks down 6.8% on average while median return down 5.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $RVMD 19.0%, $NAII 13.6%, $HROW 12.7%, $MDWD 10.9%, $TBPH 10.1%
- 1M losers are : Losers for past month are $EGRX -21.9%, $RVNC -23.9%, $SAGE -35.1%, $BLRX -46.0%, $MRNS -84.0%
- 1W winners are : Winners for past week are $MDWD 14.1%, $ACRS 6.0%, $SLN 1.9%, $RVMD 0.9%, $CPRX 0.8%
- 1W losers are : Losers for past week are $SAVA -13.2%, $RVNC -14.7%, $BLRX -15.6%, $SAGE -23.6%, $MRNS -82.2%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 10.3%, for the past 3 months is 8.1%
In the past month for a 5 days rolling window, the highest corrrelation is 18.1%, the lowest correlation is -0.2%, the latest correlation is 12.8%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 74.3% between AXSM and IRWD
The lowest correlation is -67.7% between HZNP and ICPT
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.
Sage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study, and Sage stock collapsed to a record low.
Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease. The PRECEDENT Study did not meet its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42. WAIS-IV is the
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma. The poster will be presented at the American Society for Apheresis (ASFA) 2024 Annual Meeting, taking place April 17-19, 2024, in Las Vegas, Nevada.
CAMBRIDGE, Mass., April 17, 2024--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD). The PRECEDENT Study did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on th
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity a